6 completed. 2 Phase 1, 2 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 2 |
| Phase 2 | 2 | Completed 2 |
| Phase 3 | 2 | Completed 2 |
Follow CVT-301: new trials by email Literature Review of CVT-301 trials Research Report on CVT-301
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pharmacokinetic Study of CVT-301 (Levodopa Inhalation Powder) CVT-301, Sinemet - Parkinson's Disease | Phase 1 | Completed | Acorda Therapeutics | 23 | 2019-03-05 | 2019-08-02 |
| A Study of the Safety and Levodopa Pharmacokinetics Following Single Dose Administration of CVT 301 (Levodopa Inhalation Powder) in Smoking and Non-Smoking Adults CVT-301, Carbidopa - Smoking | Phase 1 | Completed | Acorda Therapeutics | 60 | 2015-12-01 | 2016-07-14 |
| Randomized Safety Study of CVT-301 Compared to an Observational Control Group CVT-301, Observational cohort - Idiopathic Parkinson's Disease | Phase 3 | Completed | Acorda Therapeutics | 408 | 2015-03-01 | 2019-05-28 |
| Twelve Month Safety and Efficacy Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes CVT-301 - Idiopathic Parkinson's Disease | Phase 3 | Completed | Acorda Therapeutics | 325 | 2015-03-01 | 2019-08-14 |
| Efficacy and Safety Study of Inhaled CVT 301 in Parkinson's Disease Patients for Treatment of OFF Episodes CVT-301, Placebo - Idiopathic Parkinson's Disease | Phase 2 | Completed | Acorda Therapeutics | 89 | 2013-04-01 | 2018-08-08 |
| Safety, Pharmacokinetics and Efficacy Study of CVT-301 Inpatients With Parkinson's Disease and "Off" Episodes CVT-301, Placebo, Sinemet (carbidopa/levodopa) - Idiopathic Parkinson's Disease | Phase 2 | Completed | Acorda Therapeutics | 25 | 2012-05-01 | 2017-07-27 |
Parkinson Disease (5) · Smoking (1)
United States (5) · Serbia (3) · United Kingdom (3) · Czechia (2) · Israel (2) · Poland (2) · Spain (2) · Austria (1) · Belgium (1) · Canada (1) · France (1) · Germany (1) · Hungary (1) · Italy (1) · Netherlands (1)
Charles Oh, MD (3) · Harald Murck, MD, PhD (1) · Martin Freed, MD (1)